Kaiser Permanente, one of America’s largest health systems, collaborated with federal researchers on a study funded by the Centers for Disease Control and Prevention (CDC) involving a retrospective study of 6.2 million patients’ real-world records via electronic health records. The effort uncovered no serious health findings that could be causally linked to the two mRNA COVID-19 vaccines now in use. Yet the study limitations indicate some challenges to the study design.
Published recently in JAMA Network this study involved what Kaiser Permanente declared was the first comprehensive set of findings out of the Vaccine Safety Datalink (VSD), a database of patient records for 12 million patients in 5 Kaiser Permanente regions as well as HealthPartners in Minneapolis, Minnesota, the Marshfield Clinic, Wisconsin and Denver Health.
Led by Nicola Klein, MD, Ph.D., director of the Kaiser Permanente Vaccine Study and principal investigator of the Vaccine Safety Datalink’s COVID-19 rapid cycle analysis, the study was recently showcased in Jama Network.
The study team analyzed surveillance data associated with 6.2 million persons who received 11.8 million doses of ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).